Related references
Note: Only part of the references are listed.Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson et al.
BLOOD (2016)
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
Paul G. Richardson et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak et al.
BLOOD (2016)
Daratumumab in multiple myeloma
S. Vincent Rajkumar
LANCET (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
Sarah A. Holstein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2015)
Treatment options for relapsed and refractory multiple myeloma
Ajay K. Nooka et al.
BLOOD (2015)
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi et al.
BLOOD (2015)
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
David H. Vesole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
Douglas W. Sborov et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Bendamustine in multiple myeloma
Massimo Gentile et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
Patricia M. LoRusso et al.
INVESTIGATIONAL NEW DRUGS (2015)
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
Sally Martin et al.
LEUKEMIA RESEARCH (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
Salma Afifi et al.
PHARMACOTHERAPY (2015)
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
Robert Z. Orlowski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
I-Jun Lau et al.
ANNALS OF HEMATOLOGY (2015)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K. Kumar et al.
BLOOD (2015)
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Philippe Rodon et al.
HAEMATOLOGICA (2015)
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data
Antonio Palumbo et al.
LEUKEMIA & LYMPHOMA (2015)
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
Heinz Ludwig et al.
BLOOD (2014)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Jesus San-Miguel et al.
BLOOD (2014)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Shaji K. Kumar et al.
BLOOD (2014)
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Paul G. Richardson et al.
BLOOD (2014)
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Q. Ping Dou et al.
CURRENT CANCER DRUG TARGETS (2014)
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies
Tadeusz Robak et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
AKT as a therapeutic target in multiple myeloma
Niamh A. Keane et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2014)
Bruton's tyrosine kinase: potential target in human multiple myeloma
Ying Liu et al.
LEUKEMIA & LYMPHOMA (2014)
New orally active proteasome inhibitors in multiple myeloma
Alessandro Allegra et al.
LEUKEMIA RESEARCH (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
V. Munugalavadla et al.
ONCOGENE (2014)
Targeting BCL2 for the Treatment of Lymphoid Malignancies
Mary Ann Anderson et al.
SEMINARS IN HEMATOLOGY (2014)
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (vol 4, e182, 2014)
D. S. Siegel et al.
BLOOD CANCER JOURNAL (2014)
Therapeutic advancements in multiple myeloma
Alessandro Gozzetti et al.
FRONTIERS IN ONCOLOGY (2014)
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
Xavier Leleu et al.
BLOOD (2013)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
Sridurga Mithraprabhu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappa B
Stuart A. Rushworth et al.
CELLULAR SIGNALLING (2013)
Pomalidomide in the treatment of relapsed multiple myeloma
Peter A. Forsberg et al.
FUTURE ONCOLOGY (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Maria-Victoria Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets
Panisinee Lawasut et al.
SEMINARS IN ONCOLOGY (2013)
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo
J. Glauer et al.
BLOOD CANCER JOURNAL (2013)
Multiple myeloma
Dean Smith et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch et al.
BLOOD (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance
David S. Siegel
SEMINARS IN HEMATOLOGY (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Michele Cavo et al.
BLOOD (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
Masood A. Shammas et al.
BLOOD (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
C. B. Reeder et al.
LEUKEMIA (2009)
Prognostic value of immunophenotyping in multiple myeloma:: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
C. L. H. Snozek et al.
LEUKEMIA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical course of patients with relapsed multiple myeloma
SK Kumar et al.
MAYO CLINIC PROCEEDINGS (2004)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Role of interleukin-6 in the pathogenesis of multiple myeloma
K Gado et al.
CELL BIOLOGY INTERNATIONAL (2000)
Share Paper
